Treatment of Neuro-Ophthalmic Sarcoidosis

BACKGROUND:Because of the rarity of neuro-ophthalmic sarcoidosis, there are no therapeutic guidelines based on evidence-based medicine for this disorder. EVIDENCE ACQUISITION:Review of literature combined with personal experience. RESULTS:Corticosteroids are the preferred initial therapy for neuro-o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of neuro-ophthalmology 2015-03, Vol.35 (1), p.65-72
1. Verfasser:	Frohman, Larry P
Format:	Artikel
Sprache:	eng
Schlagworte:	Eye Diseases - complications Eye Diseases - therapy Humans Nervous System Diseases - complications Nervous System Diseases - therapy Neurology Ophthalmology Sarcoidosis - complications Sarcoidosis - diagnosis Sarcoidosis - therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	72
container_issue	1
container_start_page	65
container_title	Journal of neuro-ophthalmology
container_volume	35
creator	Frohman, Larry P
description	BACKGROUND:Because of the rarity of neuro-ophthalmic sarcoidosis, there are no therapeutic guidelines based on evidence-based medicine for this disorder. EVIDENCE ACQUISITION:Review of literature combined with personal experience. RESULTS:Corticosteroids are the preferred initial therapy for neuro-ophthalmic sarcoidosis. If patients cannot tolerate the requisite dose of corticosteroid needed to control their disease, or if corticosteroids fail to adequately control the disease process, the choices of a second agent are based on the consideration of rapidity of clinical response and the safety profile. CONCLUSIONS:Although methotrexate and mycophenolate mofetil are the medications that are often selected after corticosteroid failure, more rapidly acting agents that have been used are infliximab and intravenous cyclophosphamide.
doi_str_mv	10.1097/WNO.0000000000000170
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1680453106</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1680453106</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5310-df911234dc07c83bae9f444691a3d9d2857c608b14668c6af319591b52e4ad9d3</originalsourceid><addsrcrecordid>eNqNkE1LAzEURYMotlb_gUiXupia70mWUvyC0i6suAyZTIYZzTQ1maH4701pFXEhvs17i3PvgwPAOYITBGV-_TJfTODPQTk8AEPECM8Y4vww3TCHmYAYD8BJjK-JIRDLYzDAjGCGpBiCq2Wwumvtqhv7ajy3ffDZYl13tXZtY8ZPOhjflD428RQcVdpFe7bfI_B8d7ucPmSzxf3j9GaWGUYQzMpKIoQJLQ3MjSCFtrKilHKJNClliQXLDYeiQJRzYbiuCJJMooJhS3UCyAhc7nrXwb_3NnaqbaKxzumV9X1UiAtIt6_4P1DGGE5G8oTSHWqCjzHYSq1D0-rwoRBUW58q-VS_fabYxf5DX7S2_A59CUyA2AEb7zob4pvrNzao2mrX1X93fwInrX7a</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1655521537</pqid></control><display><type>article</type><title>Treatment of Neuro-Ophthalmic Sarcoidosis</title><source>MEDLINE</source><source>Journals@Ovid LWW Legacy Archive</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Frohman, Larry P</creator><creatorcontrib>Frohman, Larry P</creatorcontrib><description>BACKGROUND:Because of the rarity of neuro-ophthalmic sarcoidosis, there are no therapeutic guidelines based on evidence-based medicine for this disorder. EVIDENCE ACQUISITION:Review of literature combined with personal experience. RESULTS:Corticosteroids are the preferred initial therapy for neuro-ophthalmic sarcoidosis. If patients cannot tolerate the requisite dose of corticosteroid needed to control their disease, or if corticosteroids fail to adequately control the disease process, the choices of a second agent are based on the consideration of rapidity of clinical response and the safety profile. CONCLUSIONS:Although methotrexate and mycophenolate mofetil are the medications that are often selected after corticosteroid failure, more rapidly acting agents that have been used are infliximab and intravenous cyclophosphamide.</description><identifier>ISSN: 1070-8022</identifier><identifier>EISSN: 1536-5166</identifier><identifier>DOI: 10.1097/WNO.0000000000000170</identifier><identifier>PMID: 25325198</identifier><language>eng</language><publisher>United States: by North American Neuro-Ophthalmology Society</publisher><subject>Eye Diseases - complications ; Eye Diseases - therapy ; Humans ; Nervous System Diseases - complications ; Nervous System Diseases - therapy ; Neurology ; Ophthalmology ; Sarcoidosis - complications ; Sarcoidosis - diagnosis ; Sarcoidosis - therapy</subject><ispartof>Journal of neuro-ophthalmology, 2015-03, Vol.35 (1), p.65-72</ispartof><rights>2015 by North American Neuro-Ophthalmology Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5310-df911234dc07c83bae9f444691a3d9d2857c608b14668c6af319591b52e4ad9d3</citedby><cites>FETCH-LOGICAL-c5310-df911234dc07c83bae9f444691a3d9d2857c608b14668c6af319591b52e4ad9d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25325198$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Frohman, Larry P</creatorcontrib><title>Treatment of Neuro-Ophthalmic Sarcoidosis</title><title>Journal of neuro-ophthalmology</title><addtitle>J Neuroophthalmol</addtitle><description>BACKGROUND:Because of the rarity of neuro-ophthalmic sarcoidosis, there are no therapeutic guidelines based on evidence-based medicine for this disorder. EVIDENCE ACQUISITION:Review of literature combined with personal experience. RESULTS:Corticosteroids are the preferred initial therapy for neuro-ophthalmic sarcoidosis. If patients cannot tolerate the requisite dose of corticosteroid needed to control their disease, or if corticosteroids fail to adequately control the disease process, the choices of a second agent are based on the consideration of rapidity of clinical response and the safety profile. CONCLUSIONS:Although methotrexate and mycophenolate mofetil are the medications that are often selected after corticosteroid failure, more rapidly acting agents that have been used are infliximab and intravenous cyclophosphamide.</description><subject>Eye Diseases - complications</subject><subject>Eye Diseases - therapy</subject><subject>Humans</subject><subject>Nervous System Diseases - complications</subject><subject>Nervous System Diseases - therapy</subject><subject>Neurology</subject><subject>Ophthalmology</subject><subject>Sarcoidosis - complications</subject><subject>Sarcoidosis - diagnosis</subject><subject>Sarcoidosis - therapy</subject><issn>1070-8022</issn><issn>1536-5166</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE1LAzEURYMotlb_gUiXupia70mWUvyC0i6suAyZTIYZzTQ1maH4701pFXEhvs17i3PvgwPAOYITBGV-_TJfTODPQTk8AEPECM8Y4vww3TCHmYAYD8BJjK-JIRDLYzDAjGCGpBiCq2Wwumvtqhv7ajy3ffDZYl13tXZtY8ZPOhjflD428RQcVdpFe7bfI_B8d7ucPmSzxf3j9GaWGUYQzMpKIoQJLQ3MjSCFtrKilHKJNClliQXLDYeiQJRzYbiuCJJMooJhS3UCyAhc7nrXwb_3NnaqbaKxzumV9X1UiAtIt6_4P1DGGE5G8oTSHWqCjzHYSq1D0-rwoRBUW58q-VS_fabYxf5DX7S2_A59CUyA2AEb7zob4pvrNzao2mrX1X93fwInrX7a</recordid><startdate>201503</startdate><enddate>201503</enddate><creator>Frohman, Larry P</creator><general>by North American Neuro-Ophthalmology Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope></search><sort><creationdate>201503</creationdate><title>Treatment of Neuro-Ophthalmic Sarcoidosis</title><author>Frohman, Larry P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5310-df911234dc07c83bae9f444691a3d9d2857c608b14668c6af319591b52e4ad9d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Eye Diseases - complications</topic><topic>Eye Diseases - therapy</topic><topic>Humans</topic><topic>Nervous System Diseases - complications</topic><topic>Nervous System Diseases - therapy</topic><topic>Neurology</topic><topic>Ophthalmology</topic><topic>Sarcoidosis - complications</topic><topic>Sarcoidosis - diagnosis</topic><topic>Sarcoidosis - therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Frohman, Larry P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><jtitle>Journal of neuro-ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Frohman, Larry P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of Neuro-Ophthalmic Sarcoidosis</atitle><jtitle>Journal of neuro-ophthalmology</jtitle><addtitle>J Neuroophthalmol</addtitle><date>2015-03</date><risdate>2015</risdate><volume>35</volume><issue>1</issue><spage>65</spage><epage>72</epage><pages>65-72</pages><issn>1070-8022</issn><eissn>1536-5166</eissn><abstract>BACKGROUND:Because of the rarity of neuro-ophthalmic sarcoidosis, there are no therapeutic guidelines based on evidence-based medicine for this disorder. EVIDENCE ACQUISITION:Review of literature combined with personal experience. RESULTS:Corticosteroids are the preferred initial therapy for neuro-ophthalmic sarcoidosis. If patients cannot tolerate the requisite dose of corticosteroid needed to control their disease, or if corticosteroids fail to adequately control the disease process, the choices of a second agent are based on the consideration of rapidity of clinical response and the safety profile. CONCLUSIONS:Although methotrexate and mycophenolate mofetil are the medications that are often selected after corticosteroid failure, more rapidly acting agents that have been used are infliximab and intravenous cyclophosphamide.</abstract><cop>United States</cop><pub>by North American Neuro-Ophthalmology Society</pub><pmid>25325198</pmid><doi>10.1097/WNO.0000000000000170</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 1070-8022
ispartof	Journal of neuro-ophthalmology, 2015-03, Vol.35 (1), p.65-72
issn	1070-8022 1536-5166
language	eng
recordid	cdi_proquest_miscellaneous_1680453106
source	MEDLINE; Journals@Ovid LWW Legacy Archive; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects	Eye Diseases - complications Eye Diseases - therapy Humans Nervous System Diseases - complications Nervous System Diseases - therapy Neurology Ophthalmology Sarcoidosis - complications Sarcoidosis - diagnosis Sarcoidosis - therapy
title	Treatment of Neuro-Ophthalmic Sarcoidosis
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T18%3A32%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20Neuro-Ophthalmic%20Sarcoidosis&rft.jtitle=Journal%20of%20neuro-ophthalmology&rft.au=Frohman,%20Larry%20P&rft.date=2015-03&rft.volume=35&rft.issue=1&rft.spage=65&rft.epage=72&rft.pages=65-72&rft.issn=1070-8022&rft.eissn=1536-5166&rft_id=info:doi/10.1097/WNO.0000000000000170&rft_dat=%3Cproquest_cross%3E1680453106%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1655521537&rft_id=info:pmid/25325198&rfr_iscdi=true